Resistance to antibiotics is a great threat to global health and it can lead to a drastic negative effect in the healthcare industry. According to the recent surveyed data antibiotic and antifungal resistance is estimated to kill 35,900 people in the United States alone each year. In India, drug resistance exceeds 70 percent for many widespread bacteria, the AMF report said.
The findings of a second Antimicrobial Resistance (AMR) Benchmark report by the Access to Medicine Foundation showed that drug companies are not making progress against the spread of antibiotic resistance at a scale and speed great enough and the change is not happening at the scale needed to radically impact the problem.
Many companies such as GlaxoSmithKline, Entasis Therapeutics and Cipla are leading in antimicrobial research and development. The AMR Benchmark tests 30 companies with anti-infective business interests including international pharmaceutical companies, biotechnology firms, and generics manufacturers.